On November 16, Guardant Health Inc. fell 4.75% in Regular Trading, trading at $147.33/share, with turnover of $33.93 million.
The clearest catalyst is the settlement of the company’s $500.0 million zero-coupon convertible senior notes due 2032, which has renewed investor focus on potential future conversion dilution and financing overhang.
Company disclosures show expected net proceeds of about $538.3 million if the full option is exercised. Guardant Health Inc. plans to use about $501.7 million to repurchase roughly $395.2 million principal amount of its 2027 zero-coupon convertible notes, while the remaining proceeds together with cash on hand will fund about $51.7 million of capped call transactions intended to offset dilution from future note conversion. The transaction improves debt maturity profile, but the market reaction has been cautious despite that liability-management benefit.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments